Search

Over the last two decades, breast cancer remains the main cause of cancer deaths in women. To treat this type of cancer, radiation therapy (RT) has proved to be efficient. RT for breast cancer is, however, challenged by intrafractional motion caused by respiration. The problem is more severe for the left-sided breast cancer due to the proximity to the heart as an organ-at-risk. While particle therapy results in superior dose characteristics than conventional RT, due to the physics of particle interactions in the body, particle therapy is more sensitive to target motion.

To develop and validate a versatile Monte Carlo (MC)-based dose calculation engine to support MC-based dose verification of treatment planning systems (TPSs) and quality assurance (QA) workflows in proton therapy. The GATE MC toolkit was used to simulate a fixed horizontal active scan-based proton beam delivery (SIEMENS IONTRIS). Within the nozzle, two primary and secondary dose monitors have been designed to enable the comparison of the accuracy of dose estimation from MC simulations with respect to physical QA measurements. The developed beam model was validated against a series of commissioning measurements using pinpoint chambers and 2D array ionization chambers (IC) in terms of lateral profiles and depth dose distributions. Furthermore, beam delivery module and treatment planning has been validated against the literature deploying various clinical test cases of the AAPM TG‐119 (c-shape phantom) and a prostate patient. MC simulations showed excellent agreement with measurements in the lateral depth-dose parameters and spread-out Bragg peak (SOBP) characteristics within a maximum relative error of 0.95 mm in range, 1.83% in entrance to peak ratio, 0.27% in mean point-to-point dose difference, and 0.32% in peak location. The mean relative absolute difference between MC simulations and measurements in terms of absorbed dose in the SOBP region was 0.93% ± 0.88%. Clinical phantom studies showed a good agreement compared to research TPS (relative error for TG-119 planning target volume PTV-D 95 ∼ 1.8%; and for prostate PTV-D 95 ∼ −0.6%). We successfully developed a MC model for the pencil beam scanning system, which appears reliable for dose verification of the TPS in combination with QA information, prior to patient treatment. [ABSTRACT FROM AUTHOR]

In this study, after discretization of the neutron diffusion equation and adjoint with high-order nodal expansion method in two dimensions and two energy groups, calculations with Momentum and Galerkin weighting functions for rectangular geometry (BIBLIS-2D) and hexagonal geometry (IAEA-2D) reactors are performed. The mean of relative power error for Momentum and Galerkin weighting functions was calculated in BIBLIS-2D reactor 0.42% and 0.62%, respectively, and for IAEA-2D reactor 4.96% and 3.52%, respectively. Regarding the results, it was concluded that in order to increase accuracy with the acceptable time of computing (4 Seconds for rectangular geometry and 28 seconds for hexagonal geometry with Intelr CoreTM i7-4510U Processor), the Momentum weighting function for rectangular geometry and the Galerkin weighting function for hexagonal geometry can be used to discretize equations without reducing the node size. Therefore, to increase the accuracy while maintaining the speed of calculations, without reducing the size of nodes, the appropriate weighting function can be used in discretization, which can be very useful in performing calculations of different transients. [ABSTRACT FROM AUTHOR]

In this study, optimized preparation, quality control, cell assessments and biostribution of 188Re-HYNIC-PSMA in normal rats and tumor bearing mice are studied. Optimized conditions for radiolabeling were evaluated and radiochemical purity (> 99%) was investigated using ITLC and HPLC methods. 188Re-HYNIC-PSMA was stable both in PBS (4 °C) and in human serum (37 °C) even after 48 h. The results showed the complex was cleared from the blood very fast via urinary track. This new radiolabeled compound has a high potential to be considered as an agent for the treatment of patients with PSMA expressing tumors however more biological studies are still needed. [ABSTRACT FROM AUTHOR]